Holen Sie sich die Stockscreener-App
7.79
11.36%
0.79
Schlusskurs vom Vortag:
$7.00
Offen:
$7.295
24-Stunden-Volumen:
4.61M
Relative Volume:
1.23
Marktkapitalisierung:
$1.89B
Einnahmen:
$386.15M
Nettoeinkommen (Verlust:
$-56.39M
KGV:
-33.87
EPS:
-0.23
Netto-Cashflow:
$-55.19M
1W Leistung:
+26.75%
1M Leistung:
+34.40%
6M Leistung:
+69.46%
1J Leistung:
+45.97%
1-Tages-Spanne:
$7.219
$7.82
1-Wochen-Bereich:
$5.53
$7.82
52-Wochen-Spanne:
$3.21
$7.82
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Vergleichen Sie ARDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
7.785 | 1.70B | 386.15M | -56.39M | -55.19M | -0.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.37 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.29 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
814.78 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-02 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
BTIG Raises Ardelyx (ARDX) Price Target to $17 and Maintains Buy Rating | ARDX Stock News - GuruFocus
Ardelyx stock rises premarket as Piper sees over 100% upside — says constipation drug 'stole the show' with 2026 guidance - MSN
Ardelyx stock price target raised to $17 from $14 at BTIG on strong Ibsrela sales - Investing.com Australia
Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside — Says Constipation Drug ‘Stole The Show’ With 2026 Guidance - Stocktwits
Ardelyx Inc: Piper Sandler raises to overweight from neutral; raises target price to $16 from $10 - MarketScreener
What hedge fund moves indicate for Ardelyx Inc. (41X) stock2025 Sector Review & Weekly High Return Opportunities - ulpravda.ru
Ardelyx stock price target raised to $19 from $16 at Raymond James - Investing.com
How Ardelyx Inc. (41X) stock reacts to fiscal policies2025 Key Lessons & Weekly Momentum Picks - ulpravda.ru
Wall Street analysts see a 92.12% upside in Ardelyx (ARDX): Can the stock really move this high? - MSN
Why hedge funds are buying Ardelyx Inc. stockLayoff News & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? - Stocktwits
Ardelyx Stock Climbs Amid Revised Financial Outlook and Strategic Expansion - timothysykes.com
Why Ardelyx Inc. stock remains a top recommendation2025 EndofYear Setup & Risk Managed Investment Entry Signals - ulpravda.ru
Ardelyx stock hits 52-week high at 6.79 USD By Investing.com - Investing.com Canada
Ardelyx (ARDX) Projects Significant Revenue Growth for IBSRELA i - GuruFocus
Ardelyx stock hits 52-week high at 6.79 USD - Investing.com
Can Ardelyx Inc. (41X) stock sustain institutional flowsJobs Report & Technical Analysis for Trade Confirmation - ulpravda.ru
Is Ardelyx Inc. stock vulnerable to regulatory risksJuly 2025 Market Mood & Daily Growth Stock Tips - ulpravda.ru
Ardelyx stock rises after reporting strong 2025 revenue, upbeat 2026 outlook By Investing.com - Investing.com South Africa
Assessing Ardelyx (ARDX) Valuation After Mixed Long Term Shareholder Returns - simplywall.st
Ardelyx stock rises after reporting strong 2025 revenue, upbeat 2026 outlook - Investing.com Canada
Ardelyx reports preliminary 2025 revenue and provides 2026 strategic outlook - MarketScreener
ARDX Sees Significant Revenue Growth in 2025 - GuruFocus
Ardelyx files procedural regulatory disclosure update notice - TipRanks
Ardelyx Provides 2026 Revenue Guidance for Ibsrela, Xphozah - MarketScreener
Ardelyx Reports Preliminary 2025 Revenue And Provides 2026 Strategic Outlook - TradingView — Track All Markets
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook - The Manila Times
Constipation pill IBSRELA targets $1B in yearly sales by 2029 - Stock Titan
Long road gets longer for Ardelyx, with hope on the horizon - The Pharma Letter
Ardelyx rises amid report on price hikes for lead product - MSN
Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High? - sharewise.com
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism - MSN
How Ardelyx Inc. (41X) stock reacts to weak economy2026 world cup usa national team semifinals key players high defensive line winner prediction tactical review - ulpravda.ru
Ardelyx (NASDAQ:ARDX) Shares Down 6.9%Here's Why - MarketBeat
Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last? - Yahoo Finance
Ardelyx (ARDX) Meets Q4 Earnings Estimates - MSN
Ardelyx Stock Gains Momentum After Positive Developments - StocksToTrade
Key Developments Shaping Ardelyx’s Financial Journey - timothysykes.com
When Does Changing Course Become Securities Fraud? Court Rules Against Ardelyx Shareholders - TipRanks
Ardelyx stock jumps as Raymond James notes price hikes By Investing.com - Investing.com Australia
Ardelyx Shares Surge Following Strategic Clinical Update - timothysykes.com
Ardelyx Stock Rises Amid Market Developments - timothysykes.com
Ardelyx (ARDX) Boosts Product Prices, Shares Climb - GuruFocus
Raymond James reiterates Strong Buy on Ardelyx stock after price increases - Investing.com Nigeria
Ardelyx stock jumps as Raymond James notes price hikes - Investing.com
Ardelyx gains on price hikes for lead product (ARDX:NASDAQ) - Seeking Alpha
Jobs Data: Will Ardelyx Inc 41X stock outperform global peers2025 AllTime Highs & Expert Verified Movement Alerts - moha.gov.vn
Ardelyx Inc Stock Analysis and ForecastEarnings Growth Projections & Chat With Other Investors on Daily Signals - earlytimes.in
Raymond James reiterates Strong Buy on Ardelyx stock after price increases By Investing.com - Investing.com Nigeria
Ardelyx Insider Ups Holding By 19% During Year - Yahoo Finance
Trend Report: Why Ardelyx Inc stock is in analyst buy zoneQuarterly Investment Review & Reliable Intraday Trade Alerts - moha.gov.vn
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ardelyx Inc-Aktie (ARDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GRAMMER ELIZABETH A | See Remarks |
Nov 21 '25 |
Sale |
5.54 |
5,995 |
33,194 |
299,895 |
| RAAB MICHAEL | President & CEO |
Nov 21 '25 |
Sale |
5.54 |
46,887 |
259,609 |
1,455,363 |
| Kelliher Mike | See Remarks |
Nov 21 '25 |
Sale |
5.54 |
5,560 |
30,785 |
271,181 |
| Williams Laura A | Chief Patient Officer |
Nov 21 '25 |
Sale |
5.54 |
6,426 |
35,580 |
359,896 |
| Foster Eric Duane | Chief Commercial Officer |
Nov 21 '25 |
Sale |
5.54 |
5,814 |
32,192 |
295,684 |
| Reilly Joseph James | See Remarks |
Nov 21 '25 |
Sale |
5.54 |
11,086 |
61,382 |
108,914 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):